Business
Supernus Announces Third Quarter 2021 Financial Results
Total revenues for the first nine months of 2021 were $420.7 million; a 12% increase compared to $376.8 million in the first nine months of 2020Third quarter
About this update from Supernus Pharmaceuticals, Inc.
[{"type":"text","content":"Total revenues for the first nine months of 2021 were $420.7 million; a 12% increase compared to $376.8 million in the first nine months of 2020Third quarter 2021 total revenues were $148.5 million, a 4% decrease compared to $155.1 million in third quarter 2020Strengthen Parkinson's disease portfolio and diversify revenue and cash flow with proposed acquisition of Adamas Pharmaceuticals, Inc., announced October, 2021Launch of Qelbree™ progressing well, with accelerated prescription growth in the back-to-school seasonQelbree sNDA for adult ADHD accepted for review by FDA; PDUFA date of April 29, 2022SPN-830 (apomorphine infusion pump) NDA to be resubmitted to the FDA in November 2021Two internally discovered, novel CNS drug candidates (SPN-443 and SPN-446) nominated for development ROCKVILLE, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today reported financial results for the third quarter of 2021, and associated Company developments. Net Product Sales For the first nine months of 2021, net product sales were $412.5 million, a 12% increase over $368.6 million in the same period in 2020. The increase was primarily due to the acquisition of the CNS portfolio of US WorldMeds in June 2020. Third quarter 2021 net product sales were $145.5 million, compared to $152.1 million in the same period in 2020. The decrease was primarily due to a decrease in net product sales of APOKYN and Trokendi XR, partially offset by an increase in net product sales from other products, including Qelbree, which was launched in the second quarter of 2021. Net Product SalesThree Months endedSeptember 30, Nine Months endedSeptember 30, ($ in millions)2021 2020 Change % 2021 2020 Change %Trokendi XR®$80.9 $82.9 (2)% $231.5 $241.1 (4)%Oxtellar XR®29.7 28.3 5 % 82.1 76.0 8 %APOKYN®24.6 34.5 (29)% 73.3 43.1 70 %MYOBLOC®4.6 4.1 12 % 13.5 5.3 **XADAGO®3.3 2.3 43 % 9.4 3.1 **Qelbree2.4 — ** 2.7 — **Net Product Sales$145.5 $152.1 (4)% $412.5 $368.6 12 % Qelbree Launch Update Qelbree's growth has accelerated with the arrival of the \"back to school\" season in the third quarter of 2021, reaching total monthly prescriptions in September of 7,132, an increase of 37% compared to August, and an...